Merck (NYSE: MRK) reported Q3 EPS of $1.74, $0.31 better than the analyst estimate of $1.43. Revenue for the quarter came in at $12.6 billion versus the consensus estimate of $12.17 billion.

• Third-Quarter 2020 Worldwide Sales Were $12.6 Billion, an Increase of 1%; Excluding the Impact from Foreign Exchange, Sales Grew 2%
  • KEYTRUDA Sales Grew 21% to $3.7 Billion
  • Animal Health Sales Grew 9% to $1.2 Billion; Excluding the Impact from Foreign Exchange, Sales Grew 12%
• Third-Quarter 2020 GAAP EPS Was $1.16; Third-Quarter Non-GAAP EPS Was $1.74
• Advanced and Expanded Broad Pipeline
  • Announced Additional Positive Phase 3 Results for Investigational Pneumococcal Conjugate Vaccine (V114) in Adults
  • Presented Phase 3 Data for Investigational Gefapixant in Development for Chronic Cough; Early Data for MK-4830 in Oncology and MK-8507 for HIV
  • Expanded Pipeline with Seagen Collaborations in Oncology
• Company Advances Research Programs and Clinical Trials for COVID-19-Related Vaccine and Orally Available Antiviral Research Candidates
• Company Narrows and Raises 2020 Full-Year Revenue Range to be Between $47.6 Billion and $48.6 Billion, Including a Negative Impact from Foreign Exchange of Approximately 1.5%
• Company Narrows and Lowers 2020 Full-Year GAAP EPS Range to be Between $4.55 and $4.65; Narrows and Raises 2020 Full-Year Non-GAAP EPS Range to be Between $5.91 and $6.01, Including a Negative Impact from Foreign Exchange of Approximately 2.5%

GUIDANCE:

Merck sees FY2020 EPS of $5.91-$6.01, versus the consensus of $5.71. Merck sees FY2020 revenue of $47.6-48.6 billion, versus the consensus of $48 billion.

For earnings history and earnings-related data on Merck (MRK) click here.